GANX
Gain Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.69 / 10
Netural
Fund flow data show a 7.58/10 score with positive small-cap inflows but negative block and large-cap trends, hinting at retail-driven activity rather than institutional support. Analyst coverage is minimal, with only one opinion (Strong Buy) and a historically low win rate (20%), limiting conviction. Combined, the analyst and fund flow signals are neutral to slightly negative.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-19
InstitutionHC Wainwright & Co.
Times predicted5
Historical Win Rate20.0%
What is the market sentiment for GANX?
- GANX holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.69/10 (Netural).
